Matinas BioPharma Investor Presentation Deck

MAT2203 Value Proposition AMPHOTERICIN B 17 + ORAL ADMINISTRATION Phase 2 Cryptococcal Meningitis (Proof of Concept) LACK OF NEPHROTOXICITY LIFE CYCLE MANAGEMENT Phase 3 Invasive Aspergillosis Oral step-down therapy (Limited- or no-treatment Option Patients) VALUE Near-Term Development Strategy: Focused strategy on Phase 3 registration trial in Invasive Aspergillosis in patients with limited or no treatment options under the Limited Population Pathway for Antifungal Drugs (LPAD)* COPYRIGHT MATINAS BIOPHARMA Safe, long-term oral step-down Tx with a potent fungicidal agent 2024 LCM Treatment of Other IFIS Prophylaxis * NDA review issue MATINAS BIOPHARMA

View entire presentation